A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1991 ◽  
Vol 159 (3) ◽  
pp. 394-398 ◽  
Author(s):  
G. C. Dunbar ◽  
J. B. Cohn ◽  
L. F. Fabre ◽  
J. P. Feighner ◽  
R. R. Fieve ◽  
...  
Keyword(s):  
Side Effects ◽  
Beneficial Effect ◽  
Anxiety Symptoms ◽  
Drop Out ◽  
Antidepressant Effect ◽  
Double Blind ◽  
Group Design ◽  
Parallel Group Design ◽  
Parallel Group ◽  
Antidepressant Efficacy

To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel-group design was used, with therapy lasting six weeks. From week 2 onwards, both the 240 paroxetine-treated and the 237 imipramine-treated patients were significantly different from the 240 placebo-treated patients, but no different from each other. Side-effects with paroxetine were less likely to lead to drop-out than with imipramine. Paroxetine had a possible earlier antidepressant effect than imipramine, and a possible earlier beneficial effect on anxiety symptoms associated with depression.

New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder

2005 ◽  
Vol 20 (2) ◽  
pp. 92-95 ◽  
Author(s):  
JR Calabrese ◽  
DJ Rapport ◽  
EA Youngstrom ◽  
K. Jackson ◽  
S. Bilali ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Unmet Need ◽  
Depressive Illness ◽  
Term Treatment ◽  
Rapid Cycling ◽  
Double Blind ◽  
Parallel Group Design ◽  
Parallel Group ◽  
Long Term Treatment ◽  
Current Therapies

AbstractThe rapid cycling variant of bipolar disorder is defined as the occurrence of four periods of either manic or depressive illness within 12 months. Patients suffering from this variant of bipolar disorder have an unmet need for effective treatment. This review examines two major studies in an attempt to update understanding of the current therapies available to treat rapid cycling patients. The first trial compares lamotrigine versus placebo in 182 patients studied for 6 months. The second is a recently completed, 20-month trial comparing divalproate and lithium in 60 patients. Both trials had a double-blind, randomized parallel-group design. The data from the latter study indicate that there are no large differences in efficacy between lithium and divalproate in the long-term treatment of rapid cycling bipolar disorder. In addition, lamotrigine has the potential to complement the spectrum of lithium and divalproate through its greater efficacy for depressive symptoms.

A Clinical Study of Quazepam in Hospitalized Patients with Insomnia

1981 ◽  
Vol 9 (4) ◽  
pp. 288-291 ◽  
Author(s):  
Hans K Uhthoff ◽  
Jacques A Brunet ◽  
Anand Aggerwal ◽  
Raymond Varin
Keyword(s):  
Clinical Study ◽  
Sleep Quality ◽  
Quality Index ◽  
Adverse Reactions ◽  
Activity Index ◽  
Global Evaluation ◽  
Group Design ◽  
Parallel Group Design ◽  
Parallel Group ◽  
Hypnotic Activity

The efficacy of quazepam (Sch-16134) 15 mg capsules as a hypnotic has been compared with that of placebo in a 9-day study, using a parallel-group design. The physician's global evaluation numerically favoured quazepam 63% (nineteen of thirty) over placebo 50% (fifteen of thirty). Furthermore, it demonstrated greater improvement in Hypnotic Activity Index and Sleep Quality Index from baseline scores, and caused no adverse reactions.

scholarly journals Improving Attitudes to Volunteering Among Older Adults: A Randomized Trial Approach

2019 ◽  
Vol 42 (2) ◽  
pp. 51-61 ◽  
Author(s):  
Michelle I. Jongenelis ◽  
Ben Jackson ◽  
Jeni Warburton ◽  
Robert U. Newton ◽  
Simone Pettigrew
Keyword(s):  
Older Adults ◽  
Social Connectedness ◽  
Healthy Aging ◽  
Social Needs ◽  
Volunteer Work ◽  
Group Design ◽  
Perceptions And Attitudes ◽  
Parallel Group Design ◽  
Parallel Group ◽  
Negative Perceptions

Promoting engagement in formal volunteering represents a potential means of facilitating healthy aging. Given reluctance to participate in volunteering has been partially attributed to negative perceptions of various aspects of this activity, this study assessed whether trialing volunteering can improve perceptions among older people. Using a parallel-group design, Australians aged 60+ years ( n = 445) were randomly assigned to one of two conditions, one in which they were encouraged to trial volunteering and one in which they were asked to continue their usual activities. Perceptions and attitudes among those in the volunteering condition became significantly more favorable over 6 months relative to those in the control condition, with this change predicted by several aspects of the volunteering experience (e.g., acquisition of skills, increased social connectedness). Providing access to roles that cater to the learning and social needs of older adults appears to be important for improving attitudes toward engaging in volunteer work.

Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode

1993 ◽  
Vol 8 (6) ◽  
pp. 319-324 ◽  
Author(s):  
JP Bocksberger ◽  
JP Gachoud ◽  
J Richard ◽  
Ρ Dick
Keyword(s):  
Side Effects ◽  
Elderly Patients ◽  
Psychomotor Retardation ◽  
Antidepressant Effect ◽  
Reversible Inhibitor ◽  
Double Blind Study ◽  
Double Blind ◽  
New Class ◽  
Low Incidence ◽  
To Receive

SummaryIn a double-blind study carried out on elderly patients (older than 65 years) the efficacy and tolerability of the new antidepressant moclobemide was compared. Moclobemide belongs to a new class of substances called RIMA (Reversible inhibitor of the monoamine oxidase type A). Fluvoxamine, a selective reuptake-inhibitor of 5-HT, belongs to a class of antidepressants known for their better tolerability compared to tricyclic especially with elderly patients. Forty elderly patients (mean age 75 years) with major depression (according to DSM III) were randomized to receive either moclobemide (300 mg) or fluvoxamine (100 mg) twice daily. Dosages were increased when necessary on day 8, to a maximum of 450 mg moclobemide or 200 mg fluvoxamine and in most cases were maintained at these levels for the remainder of the study period (four weeks). Moclobemide was more effective than fluvoxamine showing a marked antidepressant effect and an earlier effect on psychomotor retardation. The two drugs were well tolerated showing a low incidence of side effects.

A Double-Blind Out-Patient Trial of Indalpine vs Mianserin

1985 ◽  
Vol 147 (3) ◽  
pp. 306-309 ◽  
Author(s):  
G. J. Naylor ◽  
B. Martin
Keyword(s):  
Side Effects ◽  
Treated Group ◽  
Blind Study ◽  
Antidepressant Effect ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference

SummaryIndalpine 150 mg per day and mianserin 60 mg per day were compared in a double-blind study of 65 depressed out-patients: 52 patients completed the 4-week trial. At the end of four weeks there was no significant difference in antidepressant effect between the two drugs; but in the first two weeks, improvement in the mianserin-treated group was significantly greater than that in the indalpine group. The mianserin-treated group reported more side-effects of sedation (eg. drowsiness, clumsiness, heaviness of limbs etc.) and one patient on indalpine developed a mild leucopenia.

Sign in / Sign up

Export Citation Format

Share Document